Announcement • Jul 28

Bicara Therapeutics Inc. Announces Board Changes

Bicara Therapeutics Inc. announced the appointments of Jeremy Bender, Ph.D., MBA and Christy Oliger to its Board of Directors. Dr. Bender most recently served as Chief Executive Officer, President and a member of the Board of Directors of Day One Biopharmaceuticals Inc. from September 2020 to April 2026, where he led the company through its evolution into a commercial-stage oncology company, including the approval and launch of OJEMDA® for pediatric low-grade glioma and the company's approximately $2.5 billion acquisition by Servier in 2026. Prior to joining Day One, Dr. Bender was Vice President of Corporate Development at Gilead Sciences Inc. from March 2018 to September 2020. Prior to that, he was Chief Operating Officer of Tizona Therapeutics Inc. from July 2015 to March 2018 and Chief Business Officer of Sutro Biopharma from October 2012 to July 2015. Prior to joining Sutro Biopharma Inc., he was Vice President of Corporate Development at Allos Therapeutics Inc. from January 2006 to September 2012. Dr. Bender began his career in the life sciences practice at Boston Consulting Group. Dr. Bender also sits on the boards of Mereo BioPharma Group plc and Aura Biosciences Inc. From October 2023 to June 2024, Dr. Bender also served as a director of Fusion Pharmaceuticals Inc. Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an MBA from the MIT Sloan School of Management. Ms. Oliger was the Senior Vice President, Business Unit Head for Oncology and Genentech from 2017-2020, managing a portfolio of 15 products, contributing U.S. revenue exceeding $13 billion, delivering launches in lung cancer, breast cancer, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), melanoma and leading an organization of more than 800 people. Prior to this role, Ms. Oliger served as Senior Vice President and Business Unit Head, Neurology, Rare Disease, Infectious disease where she was responsible for building the teams and driving successful launches in multiple sclerosis (MS) (Ocrevus®), hemophilia (Hemlibra®) and spinal muscular atrophy (SMA) (Evrysdi®). Prior to these roles, she spent three years as Global Head of Portfolio and Project Management where her team was responsible for the Late-Stage Portfolio Committee comprised of a late-stage development portfolio of greater than 300 projects across multiple therapeutic areas. Christy began her career in life sciences at Schering Plough. In addition to Bicara, Christy also currently sits on the boards of Vera Therapeutics, Karyopharm Therapeutics, and Replimune Inc. She previously served as a director at Nuvalent Inc. prior to acquisition by GSK, Sierra Oncology prior to acquisition by GSK, Reata Pharmaceuticals prior to acquisition by Biogen, Rayze Bio prior to acquisition by BMS, and Lava Oncology prior to acquisition by Xoma Therapeutics. She holds a B.A. in Economics from University of California, Santa Barbara. In addition, Kiran Mazumdar-Shaw has retired from Bicara’s Board of Directors.

Bicara Therapeutics Inc. Stock Price

BCAX Share Price Performance

BCAX Community Narratives

Pivotal Head And Neck Cancer Trial Will Reshape Prospects For This Bifunctional Antibody Developer

Phase III Progress In Head And Neck Cancer Will Reshape Long Term Outlook

Phase III Progress In Head And Neck Cancer Will Reshape Long Term Outlook

Pivotal Head And Neck Cancer Trial Will Reshape Prospects For This Bifunctional Antibody Developer

Trending Discussion

Recently Updated Narratives

Phase III Progress In Head And Neck Cancer Will Reshape Long Term Outlook

Pivotal Head And Neck Cancer Trial Will Reshape Prospects For This Bifunctional Antibody Developer

Snowflake Analysis

Bicara Therapeutics Inc. Key Details

About BCAX

Recent BCAX News & Updates

Bicara Therapeutics Inc. Announces Board Changes

Chief Legal Officer notifies of intention to sell stock

Bicara Therapeutics Secures Funding and Breakthrough Status as FICERA Advances Toward Phase III Milestone

Recent updates

Bicara Therapeutics Inc. Competitors

Apogee Therapeutics

Halozyme Therapeutics

Bruker

Avantor